Gold therapy in rheumatoid arthritis
and renal complications in 16 (14%); 7 (6%) developed haematological complications, which resulted in death in 2 cases.
HLA tissue typing in 37' patients with side-effects showed no increase in the HLA Dw2 or HLA Dw3 antigen. There was, however, a significant increase in the HLA DRw4 antigen in both Whites and Coloureds (P :::;; 0,008 and P:::;; 0,001 respectively). Gold salt were first used in the treatment of tuberculosis by Koch in 1980. In 1928 Forrestier, believing there to be clinical similarities between tuberculosis and rheumatoid arthritis, used gold saltS for the treatment of the latter condition. His experience, for which he claimed a 70-80% success rate in over 500 patients, was first published in 1934. 1 Since that time the use of gold compounds in the treatment of rheumatoid arthritis has been well documented,z-6 but despite their beneficial effects their freer use is limited by side-effects.
Our 8-year experience with sodium aurothiomalate (Myocrisin) in patients with rheumatoid arthritis attending the arthritis clinics at Groote Schuur Hospital and Princess Alice Orthopaedic Hospital is presented. relationship between serum gold levels and clinical response was demonstrable. Therapy was discontinued in 58 patients, sideeffects being the main reason (Table I) .
Side-effects (Table II) . Mucocuraneous reaClions were the commonest side-effects encountered. A total of 41 (39%) had skin rashes, and 4 of these also had stomatitis. Most ofthe rashes were nonspecific and associated with pruritus. The skin reactions were usually mild and mOST responded to discontinuation of or reduction in the dosage of sodium aurothiomalate. A few patients required topical corticosteroids, and 1 patient was treated with systemic corticosteroids. No correlation between eosinophilia ll!ld the development of skin reactions was found. 
No. of Patients
The results reflect the data·from 104 completed protocols. The age of onset of rheuinatoid arthritis ranged from 12 to 70 years, with a mean of 42 years. The duration of disease before chrysotherapy was 6 months -25 years, with a mean of 8 years. The grades of severity at the start of chrysotherapy were: 1 patient -grade 1, 56 patients -grade 2, and 47 patientsgrade 3. All the patients were taking non-steroidal antiinfla=atory drugs. Thirty-one (29,8%) were on corticosteroids and 2 (1,9%) on chloroquine; 4 (3,8%) had previously received penicillamine. Sodium aurothiomalate administration was started in these patients either because of failure to respond to other agents or because of severe progressive disease. The duration of chrysotherapy varied from 3 weeks to 89 months, with a mean of 19,3 months. Six of the patients received two courses. Rheumatoid factor tests performed in 101 patients were positive in 64 and negative in 37. Seroconversion occurred in 19 seropositive patients and in 6 there was a reduction in titre. In 1 patient a negative test converted to positive.
The results of therapy can be seen in Figs 1, 2 and 3. Forty patients (38,5%) with a mean duration of disease of 7 years went into remission; this occurred within the fIrst year oftherapy in 28 patients. Twenty-four of the patients in remission were seropositive; in 14 of them seroconversion took place and in 2 there was a reduction in titre. The duration of remission varied from 2 to 60 months, with a mean of20 months. Thirty (28,84%) improved their grade of activity. Improvement began most commonly within the first year. In the 30 patients who improved by at least 1-2 grades the mean duration of disease was 7 years. In this group 20 were seropositive; in 5 ofthem seroconversion took place and in 1 there was a reduction in titre. Seven of the 104 patients (6,7%) did not respond to sodium aurothiomalate. No
Results
A total of 114 patients was treated during the period 1971-1979; all had either classic or definite rheumatoid arthritis. 7 Sodium aurothiomalate was injected intramuscularly as follows: an initial dose of 10 mg was followed by 20 mg 1 week later, and thereafter by 50 mg weekly to a total dose of 1 g; 50 mg was administered every 2 weeks thereafter and attempts were made to decrease the frequency ofadministration to every 3 or 4 weeks. The severity of disease activity was graded using a scale from 0 to 3: 8 grade 0 (remission) -no persistent joint pain, swelling or morning stiffness; grade 1 (mild disease) -persistent joint pain without tenderness, swelling or morning stiffness; grade 2 (moderate disease) -the presence of joint pain, tenderness and swelling with morning stiffness for less than 2 hours; and grade 3 (severe disease) -persistent joint pain, tenderness and swelling with severe morning stiffness for more than 2 hours. The clinical grades were recorded at the start of chrysotherapy and at intervals of 1, 2, 3, 6, 9, 12, 18 and 24 months, and then at yearly intervals thereafter. Failed therapy was defmed as no improvement after 6 months of treatment. At each visit the patient'S urine was tested, a blood count (white cell count, platelet count, haemoglobin concentration and ESR) was performed and the serum gold level was measured.
When side-effects were noted, sodium aurothiomalate was discontinued either permanently or temporarily or the dosage was reduced, depending on the nature and severity of the sideeffects. Administration of the compound was discontinued for the following reasons: severe skin rashes, haematological abnormalities (leucopenia or thrombocytopenia) or urinary abnormalities. When possible, tissue typing was done in patients who had had toxic reactions. Rheumatoid factor tests (sheep cell agglutination and latex) were performed initially and at intervals thereafter. 
Patients and methods

Discussion
Our data support the general view that ofevery 100 patients who starr chrysotherapy one-half to two-thirds will improve, 20 will not benefit and 25-40 will develop toxic reactions. 9 Sodium aurothiomalate is usually given to patients who have early, active progressive disease which has not responded to other forms of therapy. In many of the controlled studies of chrysotherapy the duration of disease before therapy has been about 2 years. This is also the period during which spontaneous remissions are more likely to occur. It is claimed that patients with longstanding disease do not respond as well. This is based on the assumption that longstanding disease is associated with structural damage. The co-operative clinics study,'O however, showed that the duration of the disease did not predict o.utcome. Our data support this, since the mean duration of the disease before chrysotherapy was 8 years (7 years in those who went into remission). Remission in our patients has been maintained for periods varying from 2 to 60 months. Sodium aurothiomalate administration was not discontinued during remission, since it is now customary to continue treatment indefinitely to prevent relapse.
• 8 ,1O
The value of continuing chrysotherapy after remission has, however, been questioned by Cats,ll who in a controlled study found that improvement was maintained for as long as 3 years whether or not chrysotherapy was continued.
It is claimed that the test for rheumatoid factor in patients receiving sodium aurothiomalate seldom converts from positive to negative, although a reduction in titre is usually found. 3 • 1o Of the 70 patients in our series who improved, 44 were seropositive; in 19 of them seroconversion took place and in 3 there was a reduction in titre.
Although we demonstrated clinical and serological improvement with chrysotherapy, side-effects constitute the main reason for discontinuation of therapy. This is the major limiting factor in the use of sodium aurothiomalate for rheumatoid arthritis, 12,13 the main adverse reactions encountered involving the skin, bone marrow and kidneys.
Mucocutaneous reactions were the most common toxic reactions. The skin reactions are usually not severe but chrysotherapy was discontinued in 18 patients because 'of severe reactions. A skin rash occurring in patients who receive chrysotherapy presents a problem, because the manifestations are nonspecific and polymorphic and may be unrelated to therapy. An associated eosinophilia may provide a possible clue to the cause of the rash,l4 but skin biopsies including immunofluorescence tests are not helpful, except in lichenoid reactions. TO correlation betWeen the onset of mucocutaneous reactions and the presence of eosinophilia could be demonstrated in this study, neither could a correlation between the total dosage of sodium aurothiomalate and skin reactions be demonstrated. The dosage at which skin reactions occurred varied from 140 to 3200 mg.
Haemacological abnormalities. Seven patients (6%) developed thrombocytopenia; 2 of these died owing to intracerebral haemorrhage. In the remainder the thrombocytopenia produced no symptoms and responded to discontinuation of therapy. In most of these patients the thrombocytopenia occurred before the patient had received I g sodium aurothiomalate.
Other adverse reaceions. One patient developed a postinjection reaction and I a postinjection flare.
In 37 patients with side-effects HLA tissue typing was done for the D locus antigen. White and Coloured patients were analysed separately because of differences in genetic make-up. There was no significant increase ofthe HLA Dw2 or HLA Dw3 antigen in either of the groups, while the HLA DRw4 antigen was significantly increased (P~0,008 and P~0,001 respectively). There was no significant increase in the HLA B8 antigen in 11 of the 16 patients with proteinuria. Renal complicarions. Proteinuria was noted in 16 patients. In 9 it was intermirtent and present in trace amounts only. In 7 patients who developed significant proteinuria sodium aurothiomalate administration was discontinued permanently. Proteinuria resolved completely in all patients, including I with the nephrotic syndrome.
It is not always necessary to discontinue the drug permanently if a skin rash appear . Temporary cessation of or reduction in the dose may permit its continued use. Topical steroids may be used but systemic conico teroids are rarely required.
Transient proteinuria frequently occurs. I; It is usually mild, readily reversible and rarely proceeds to the nephrotic syndrome. No one ha really investigated the nature of the renal lesion in these patient. If the nephrotic syndrome develops, it is usually a membranous glomerulonephritis characterized by electron-dense deposits containing C3 and IgG in the basement membrane. 16 In the patient who developed the nephrotic syndrome, immunofluorescence studies on the renal biopsy specimen were not helpful while electron microscopy revealed marked gold deposition in the glomeruli, especially in the mesangial and subepithelial regions.
lephropathy caused by gold salts has been shown to occur more commonly in cases of seronegative rheumatoid arthritis. 17 Our data support this, since 9 (56%) of the 16 patients who developed proteinuria were seronegative. The prognosis is usually good and the appearance of nephropathy caused by gold does not necessitate permanent cessation of therapy in all cases. Only 6 patients required permanent withdrawal of the gold compound because of significant proteinuria; in the remainder it was withheld until the proteinuria cleared and then reintroduced at a lower dosage. The proteinuria did not recur in any of these patients.
The haematological complications of chrysotherapy are fortunately uncommon and include leucofenia, agranulocytosis, thrombocytopenia and aplastic anaemia..12,13 Of these, aplastic anaemia carries the worst prognosis. Two of the 7 patients who developed haematological complications died from cerebral haemorrhage due to thrombocytopenia. The presentation in these patients was dramatic and worthy ofcomment. One patient developed thrombocytopenia and anaemia after 1,14 g sodium aurothiomalate. The bone marrow showed hypercellularity with increased megakaryocytes, and the thrombocytopenia was anributed to peripheral consumption of platelets. In the other patient thrombocytopenia followed 6 weeks after withdrawal of sodium aurothiomalate owing to a skin rash. This patient showed a generalized marrow hypoplasia. Despite high-dose corticosteroid therapy the thrombocytopenia persisted. Neither of these fatal cases was predictable by regular blood counts. This is in agreement with the experience of others IS that there seems to be no relationship between the duration of chrysotherapy and the onset of thrombocytopenia.
Kean and Anastassiades 1s suggest that when there is a trend for the platelet count to decrease, even if it is still above 200 000/ pi, the dosage should be re-evaluated. The platelet count depends on the handling of the blood and on the reliability of the method used for its determination.
In contrast to the studies of Wooley er al., 19 we were unable to show an association between the development ofside-effects and the HLA DRw2 or DRw3 antigen or between HLA BB and proteinuria. The increase in HLA DRw4 probably reflects the association between this antigen and classic or definite rheumatoid arthritis. 20 Despite its numerous side-effects, chrysotherapy still has a place in the treatment of rheumatoid arthritis. With careful monitoring the development of serious reactions can be reduced. The unpredictability of a sudden onset of thrombocytopenia or bone marrow aplasia, however, remains a m!1jor problem. . We wish to thank Sisters M. C. Murray and E. Steyn for their invaluable assistance in the clinics.
